Zhitong Finance App News, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (Laimei Longyu for short), a wholly-owned subsidiary of the company, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” approved and issued by the State Drug Administration. Fenelidone is a nonsteroidal selective halocorticoid receptor (MR) antagonist whose formulation is used to treat adult patients with chronic kidney disease associated with type 2 diabetes.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.